Prevalence and risk factors of nutritional anaemia among adolescents in India: a systematic review with meta-analysis of prevalence.

Ann MedAug 18, 2026 (epub)
Clinical ResearchPediatricsPreventive Medicine / Public HealthOpen access

Porselvi Arumugam, Priya Manirajan, Palanisamy Sivanandy

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed the prevalence of nutritional anaemia among Indian adolescents aged 10-19 years, analyzing data from 45 studies involving 159,979 participants. The findings revealed a pooled prevalence of 56% (95% CI: 49%-63%), with significantly higher rates in girls (62%) compared to boys (39%).

Key findings

  • The pooled prevalence of nutritional anaemia among Indian adolescents was 56%.
  • Anaemia prevalence was higher in girls (62%) than boys (39%).
  • Iron deficiency was associated with a higher risk of anaemia (OR 2.38-4.68).
  • Low socioeconomic status and poor dietary diversity were significant risk factors.

Why it matters

Nutritional anaemia poses a significant public health challenge, affecting physical growth and cognitive development in adolescents. Understanding its prevalence and risk factors is crucial for developing effective interventions.

Source

PubMed · PMID 42610344Free full text on PubMed Central

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.